Physician profile
Anna Farmer
NPI 1831460666
$8,709.50
in general payments reported to CMS, 2019-2025
24 companies · $770 in 2025
The $770 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $904 · 2022: $875 · 2023: $1,825 · 2024: $4,336 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,667 · Travel and Lodging: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,667.40 |
| Travel and Lodging | $2,263.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $6,085.27 | 2022-2025 | Inspire |
| Alk-Abello, INC | $441.48 | 2022-2024 | Grastek, Ragwitek, Odactra |
| Otsuka America Pharmaceutical, INC. | $375.01 | 2022-2024 | Rexulti |
| Abbvie INC. | $271.02 | 2021-2022 | |
| Novo Nordisk INC | $135.92 | 2021-2022 | |
| Genzyme Corporation | $125.00 | 2021 | |
| Mirati Therapeutics, INC. | $120.57 | 2023 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $116.37 | 2023 | Reblozyl |
| Teva Pharmaceuticals USA, INC. | $114.30 | 2021 | |
| Neurocrine Biosciences, INC. | $112.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $97.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $97.58 | 2022 | |
| Inari Medical, INC. | $94.48 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $94.10 | 2022 | |
| Esperion Therapeutics, INC. | $89.88 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.70 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.60 | 2021 | |
| Stryker Corporation | $38.74 | 2022-2024 | Audion Et Dilation System |
| Acclarent, INC | $37.63 | 2024 | Acclarent Aera |
| Integra Lifesciences Corporation | $37.60 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Glaxosmithkline, LLC. | $30.49 | 2021-2024 | Nucala |
| Optinose US, INC. | $22.96 | 2024 | |
| Smith+Nephew, INC. | $22.57 | 2024 | Tula |
| Kowa Pharmaceuticals America, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.